CHF Solutions

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDEN PRAIRIE, Minn., May  01, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (CHFS) today announced the pricing of a registered direct offering of 3,597,880 shares of its common stock at a price of $0.4725 per share, for gross proceeds of approximately $1.7 million, prior to deduction of commissions and offering expenses payable by CHF Solutions. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 1,798,940 shares of the Company’s common stock.

CHF Solutions, Inc. Announces Registered Direct Offering Priced At-the-Market

EDEN PRAIRIE, Minn., May  01, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced that it has shipped Aquadex product to a specialty care center designated for the most severe COVID-19 patients in Minnesota.

CHF Solutions Ships Aquadex Product to COVID-19 Specialty Center in Minnesota

EDEN PRAIRIE, Minn., April  21, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a small and growing medical device company dedicated to changing the lives of patients suffering from fluid overload, announced receipt of $1.66 million under the Paycheck Protection Program (PPP) under the federal Coronavirus Aid, Relief, and Economic Security (CARES) Act. This amount represents the full amount available to the company, based on its payroll expense. In addition, the company has received approximately $1.1 million in proceeds from the exercise of outstanding warrants.

CHF Solutions Receives $1.66 Million under SBA’s Paycheck Protection Program and $1.1 Million from Warrant Exercises

EDEN PRAIRIE, Minn., April  16, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, announced increased utilization of its Aquadex therapy in patients affected by COVID-19. Product sales of the Aquadex therapy to six hospitals in New York City, the epicenter of the pandemic in the U.S., have increased over 300% in the last thirty days, as compared to the monthly-average for 2019. The company is still evaluating the impact the pandemic may have on its overall business.

CHF Solutions Announces 300% Increase in Utilization of Aquadex Therapy in NYC Hospitals, the Epicenter of COVID-19

Citing Risk of Acute Kidney Injury, April 10th Physician-led Webinar Presented Real World Case Studies on Patients with COVID-19 Citing Risk of Acute Kidney Injury, April 10th Physician-led Webinar Presented Real World Case Studies on Patients with COVID-19

CHF Solutions Announces COVID-19 Patients Treated with Aquadex Therapy for Fluid Management When Access to Dialysis Machines is Limited or Not Available

EDEN PRAIRIE, Minn., April  08, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced the company will host an interactive, clinician-led webinar to discuss cardio-pulmonary-renal management in real-world COVID-19 patients. Dr. Daniel J. Goldstein, Professor & Vice Chairman, Department of Cardiothoracic Surgery, Montefiore Medical Center, New York will moderate the online discussion on Friday, April 10 at 1:00 p.m. EDT.

CHF Solutions Convene Physicians to Discuss Cardio-Pulmonary-Renal Management of COVID-19 Patients

EDEN PRAIRIE, Minn., April  02, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, announced that it has doubled the production staff that builds its next generation Aquadex SmartFlow consoles in response to increased demand from hospitals due to the coronavirus COVID-19.

CHF Solutions Doubles Production Staff of Aquadex SmartFlow™ Consoles Due to Hospital Demand

EDEN PRAIRIE, Minn., March  30, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the pricing of a registered direct offering of 5,130,228 shares of its common stock at a price to the public of $0.434 per share, for gross proceeds of approximately $2,226,000, prior to deduction of commissions and offering expenses payable by CHF Solutions. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 2,565,114 shares of the Company’s common stock.

CHF Solutions, Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market

EDEN PRAIRIE, Minn., March  20, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the pricing of a registered direct offering of 4,161,392 shares of its common stock at a price to the public of $0.30 per share, for gross proceeds of approximately $1,248,000, prior to deduction of commissions and offering expenses payable by CHF Solutions. In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 4,161,392 shares of the Company’s common stock.

CHF Solutions, Inc. Announces Pricing of Registered Direct Offering

EDEN PRAIRIE, Minn., March  19, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the Aquadex FlexFlow system has been licensed and approved for sale in India, making ultrafiltration therapy available for patients suffering from hypervolemia, or fluid overload, in one of the largest countries in the world.

CHF Solutions’ Aquadex FlexFlow® System is licensed and approved for sale in India

Proper Control of Fluids Routinely Administered to Patients with Acute Respiratory Infections Play Important Role in Successful Outcomes Proper Control of Fluids Routinely Administered to Patients with Acute Respiratory Infections Play Important Role in Successful Outcomes

CHF Solutions Webinar Highlighted Importance of Fluid Management in Patients Treated for COVID-19

CHF Solutions' (CHFS) CEO John Erb on Q4 2019 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn., Feb.  12, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the initiation of distribution agreements covering Germany, Austria and Switzerland with Neucomed Group and its affiliates, further expanding its commercial presence in the European Union. The company now has distribution partnerships covering 13 countries worldwide.

CHF Solutions Expands Commercial Presence in Europe with Distribution Arrangement for Germany, Austria and Switzerland

EDEN PRAIRIE, Minn., Feb.  11, 2020  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS), today announced that, on February 5, 2020, the independent directors approved five equity awards under CHF Solution’s New-Hire Equity Incentive Plan, as material inducements to five individuals entering into employment with the Company.  The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

CHF Solutions, Inc.  Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

EDEN PRAIRIE, Minn., Feb.  05, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the receipt of a CE Mark for its Aquadex SmartFlow console, its next generation ultrafiltration system. The console is a simple, flexible and smart solution for treatment of patients suffering from fluid overload and will be used in the European Union with adult and pediatric patients who weigh 20kg or more.

CHF Solutions Receives CE Mark for its New Aquadex SmartFlow™ Console

EDEN PRAIRIE, Minn., Jan.  30, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the filing of four patent applications with the United States Patent and Trademark Office (USPTO) to protect new innovations for use in aquapheresis therapy and further strengthen the company’s intellectual property protection for its Aquadex FlexFlow® system.

CHF Solutions Expands its Patent Portfolio with Four Applications for Innovations for Aquapheresis Therapy

EDEN PRAIRIE, Minn., Jan.  28, 2020  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) today announced the closing of an underwritten public offering of units for gross proceeds of approximately $9.66 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions.

CHF Solutions, Inc. Announces Closing of $9.66 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

EDEN PRAIRIE, Minn., Jan.  24, 2020  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ:CHFS) today announced the pricing of an underwritten public offering of units for gross proceeds of approximately $8.4 million prior to deducting underwriting discounts and commissions and offering expenses payable by CHF Solutions. The offering is comprised of (1) 3,755,458 Class A Units, priced at a public offering price of $0.55 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $0.55 per share that expires on the fifth anniversary of the date of issuance, and (2) 11,517,269 Class B Units, priced at a public offering price of $0.55 per unit, with each unit consisting of one share of Series H convertible preferred stock, convertible into one share of common stock, and a warrant to purchase one share of common stock with an exercise price of $0.55 per share.

CHF Solutions, Inc. Announces Pricing of $8.4 Million Underwritten Public Offering

EDEN PRAIRIE, Minn., Jan.  22, 2020  (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced that Texas-based health system, Baylor Scott & White Health has initiated offering aquapheresis therapy using the company’s Aquadex FlexFlow® system at its Baylor Scott & White Medical Center in Temple, Texas.

CHF Solutions Announces Launch of Aquapheresis Therapy Using Aquadex FlexFlow® System at the Baylor Scott & White Health System in Texas

EDEN PRAIRIE, Minn., Nov.  15, 2019  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (NASDAQ: CHFS), today announced that, on November 12, 2019, the independent directors approved eight equity awards under CHF Solution’s New-Hire Equity Incentive Plan, as material inducements to eight individuals entering into employment with the Company. The equity awards were approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

CHF Solutions, Inc. (CHFS) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CHF Solutions, Inc. (CHFS) CEO John Erb on Q3 2019 Results - Earnings Call Transcript

EDEN PRAIRIE, Minn., Nov.  04, 2019  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (CHF Solutions or the Company) (NASDAQ:CHFS) today announced the pricing of a registered direct offering of 1,219,076 shares of its common stock (or common equivalents) at a price to the public of $1.12 per share, for gross proceeds of approximately $1.36 million prior to deduction of commissions and offering expenses payable by CHF Solutions.  In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 1,219,076 shares of the Company’s common stock.

CHF Solutions, Inc. Announces  Pricing of Registered Direct Offering Priced At-the-Market

EDEN PRAIRIE, Minn., Oct.  23, 2019  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (CHF Solutions or the Company) (NASDAQ:CHFS) today announced the pricing of a registered direct offering of 575,830 shares of its common stock at a price to the public of $1.15 per share, for gross proceeds of approximately $660,000, prior to deduction of commissions and offering expenses payable by CHF Solutions.  In a concurrent private placement, the Company agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to 575,830 shares of the Company’s common stock.

CHF Solutions, Inc.  Announces  Pricing of Registered Direct Offering

EDEN PRAIRIE, Minn., Oct.  17, 2019  (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) today announced that it will be exhibiting at the American College of Chest Physicians’ (CHEST) Annual Meeting 2019, on October 21-23, 2019. The conference will be held at the Ernest N. Morial Convention Center in New Orleans, La.  The company will be found at Exhibit Booth #2626.

CHF Solutions to Exhibit at The American College of Chest Physicians (CHEST) Annual Meeting 2019

CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics.

News for CHF Solutions Stock (CHFS)